CD163 Polyclonal Antibody, Cy3 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-2527R-Cy3 |
| Product Name | CD163 Polyclonal Antibody, Cy3 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CD163/M130 |
| Immunogen Range | 1001-1121/1156 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9332 |
| Swiss Prot | Q86VB7 |
| Subcellular location | Secreted, Cell membrane |
| Synonyms | M13; MM13; Scavenger receptor cysteine-rich type 1 protein M13; Hemoglobin scavenger receptor; CD163, M130 |
| Background | Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells. After shedding, the soluble form (sCD163) may play an anti-inflammatory role, and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |